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Common sequence variants have recently joined rare structural polymorphisms as genetic factors with
strong evidence for association with schizophrenia. Here we extend our previous genome-wide association
study and meta-analysis (totalling 7 946 cases and 19 036 controls) by examining an expanded set of variants
using an enlarged follow-up sample (up to 10 260 cases and 23 500 controls). In addition to previously
reported alleles in the major histocompatibility complex region, near neurogranin (NRGN) and in an intron
of transcription factor 4 (TCF4), we find two novel variants showing genome-wide significant association:
rs2312147[C], upstream of vaccinia-related kinase 2 (VRK2) [odds ratio (OR) 5 1.09, P 5 1.9 3 1029] and
rs4309482[A], between coiled-coiled domain containing 68 (CCDC68) and TCF4, about 400 kb from the
previously described risk allele, but not accounted for by its association (OR 5 1.09, P 5 7.8 3 1029).
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INTRODUCTION
Recent results support a contribution of common variants to
schizophrenia heritability. Variants showing genome-wide
significant association with schizophrenia have been reported
in zinc finger binding protein 804A (ZNF804A) at 2q32.1 (1),
in the major histocompatibility complex (MHC) region at
6p21.3–22.1 (2–4), near NRGN at 11q24.2 (4) and in TCF4
at 18q21.2 (4). In addition, score alleles—or alleles with
some, although not necessarily strong, evidence for association
in a discovery data set—have been shown to be significantly
enriched in schizophrenia patients of independent data sets
(2). Based on comparison of various score allele sets and
results from simulations under different genetic models, the
best-fitting heritability model has been determined to include
a polygenetic component composed of a large number of
common alleles, each conferring a small risk but together
accounting for at least one-third of narrow-sense heritability (2).
We previously carried out the SGENE-plus genome-wide
association (GWA) study of schizophrenia (2 663 cases;
13 498 controls) with subsequent combination of results
from the top 1500 single-nucleotide polymorphisms (SNPs)
with data from the International Schizophrenia Consortium
(ISC) (2 602 cases; 2 885 controls) and the Molecular Genetics
of Schizophrenia (MGS) group (2 681 cases; 2 653 controls)
(4). SNPs having P-values , 1 × 1025 in the combined
SGENE-plus-ISC-MGS data set were followed-up in an
additional 4 999 cases and 15 555 controls.
Here we extended our earlier study by examining loci
having P, 1 × 1024 in the SGENE-plus-ISC-MGS data set.
All SNPs were tested in 19 European and European-American
study groups (9 246 cases and 22 356 controls; Supplementary
Material, Table S1), and those attaining genome-wide signifi-
cance in a joint analysis (SGENE-plus-ISC-MGS and
follow-up) were investigated in an additional 1 014 cases
and 1 144 controls from Germany.
RESULTS
We chose SNPs for follow-up by filtering SNPs having
P-values , 1 × 1024 in the SGENE-plus-MGS-ISC data set
so that no SNP in the final set had r2 . 0.3 with another—
except in the MHC region where the two SNPs having the
most significant combined P-values in our previous study (4)
were retained. Altogether, 39 SNPs were examined, one per
genomic region apart from the MHC region and at 18q21.2
where 6 and 2 SNPs, respectively, were investigated. Allelic
association analysis was carried out in 19 European and Euro-
pean-American study groups, and inverse-variance-weighted
meta-analysis was used to combine the results.
Of the 33 genomic regions tested, 30 had, for the most sig-
nificant regional SNP in the SGENE-plus-ISC-MGS data set,
an effect in the same direction as in the discovery data set
(Supplementary Material, Table S2). This pattern of excess
is unlikely to occur by chance (P ¼ 7.0 × 1027) implying
enrichment of the follow-up set of variants for schizophrenia
risk alleles.
In the combination of the follow-up and SGENE-
plus-ISC-MGS results, eight SNPs, including two that were
novel, showed genome-wide significance (P, 5 × 1028)
(Supplementary Material, Table S2). These SNPs continued
to show genome-wide significant association after the
addition of data from a further 1 014 cases and 1 144 controls
(Tables 1 and 2).
The newly identified variants showing genome-wide signifi-
cant association were located at 2p15.1, near VRK2, and at
18q21.2, between CCDC68 and TCF4 (Table 1 and see Sup-
plementary Material, Figures S1 and S2 for illustrations of
the regions). In both cases, association did not deviate from
the multiplicative model for risk (P ¼ 0.33 for rs2312147;
P ¼ 0.68 for rs4309482), and there was no evidence of
odds ratio (OR) heterogeneity between the study groups
(P ¼ 0.82, I2¼ 0 for rs2312147; P ¼ 0.74, I2¼ 0 for
rs4309482; see Supplementary Material, Tables S3 and S4
for association results by study group). Although rs4309482
is located 400 kb from rs9960767, a SNP previously
shown to be associated with schizophrenia by us, the two
SNPs are only very weakly correlated (in the study groups
with individual genotypes available, D′ , 0.8, r2, 0.03),
and the association of neither SNP could be explained by
the other (in the study groups with individual genotypes avail-
able, rs4309482 had a P-value of 6.3 × 1027 while, con-
ditional on rs9960767, it had a P-value of 4.4 × 1026; in the
same groups, rs9960767 had a P-value of 1.1 × 1025, while,
conditional on rs4309482, it had a P-value of 7.8 × 1025).
The previously identified SNPs showing genome-wide
significance were located in three genomic locations: two sub-
regions of the MHC (one extending from 27.2 to 28.4 Mb and
the other 32.3 Mb), near NRGN, and in an intron of TCF4
(Table 2 and see Supplementary Material, Figures S2–S4
for illustrations of the regions). The strongest association in
the telomeric MHC sub-region was at rs13211507 (Table 2),
in contrast to our previous investigation where the most sig-
nificant association in that sub-region was at rs6932590.
However, as in our earlier work, the most significant SNP in
the telomeric sub-region was not strongly correlated with the
significant SNP in the centromeric sub-region (in the study
groups for which genotypes were available, r2  0.2, D′ 
0.6), and the association of neither SNP could explain that
of the other (in groups with individual genotypes available,
rs13211507 had a P-value of 1.3 × 1028, while conditional
on rs3131296, the P-value was 2.1 × 1024; in the same
groups, rs3131296 had a P-value of 3.9 × 1028, while con-
ditional on rs13211507, the P-value was 6.8 × 1024). No
deviation from the multiplicative model for risk (P . 0.12),
or evidence of OR heterogeneity between the study groups
(P . 0.13, I2 , 23, see Supplementary Material, Tables
S5–S8 for results by study group), was observed for any of the
previously identified SNPs showing genome-wide significance.
In the combination of the follow-up and the
SGENE-plus-ISC-MGS data sets, four variants had P-values
that did not surpass our genome-wide significance threshold
but were below 1 × 1026 (Supplementary Material,
Table S2). These variants—located at 5q21.1, near solute
carrier organic anion transporter family member 6A1
(SLCO6A1); at 8q21.3 in matrix metallopeptidase 16
(MMP16); at 11q23.2 between dopamine receptor D2 (DRD2)
and transmembrane protease serine 5 (TMPRSS5); and at
10q24.32 in arsenic (+3 oxidation state) methyltransferase
(AS3MT)—warrant further study.
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DISCUSSION
In this work, we found two new variants, one at 2p15.1 and the
other at 18q21.2, showing genome-wide significant association
with schizophrenia. Six other variants—in the MHC region, at
11q24.2 and at 18q21.2—continued to show genome-wide
significant association.
The novel variant at 2p15.1, rs2312147[C], is located
50 kb upstream of VRK2, a gene coding for a serine/threo-
nine kinase belonging to the casein kinase I group (5).
VRK2 is widely expressed, with elevated expression in
highly proliferative cells (6). Alternatively spliced transcripts
result in multiple isoforms (7). VRK2 has been proposed to
play a role in the maintenance of appropriate nuclear architec-
ture (8), and to be involved in preventing apoptosis (9). The
serine/threonine kinase binds JIP1 [Jun NH2-terminal Kinase
(JNK) Interacting Protein 1] (10) which in neuronal cells,
serves as an anti-apoptotic factor in response to stress (11)
and plays a role in axonal development (12).
A second gene, Fanconi anemia complementation group L
(FANCL), is located in the same linkage disequilibrium
block as VRK2 (Supplementary Material, Figure S1).
FANCL ubiquitylates Fanconi anemia group D2 (FANCD2)
and Fanconi anemia complementation group I (FANCI),
promoting DNA-interstrand crosslink repair (13).
The newly identified risk factor at 18q21.2, rs4309482[A],
lies approximately equidistant from CCDC68 and TCF4, and
could act through either gene or both. The association with
schizophrenia of rs9960767[C]—located in intron 3 of
TCF4—makes the simplest model one in which TCF4 is
affected by both variants.
TCF4 encodes a basic helix-loop-helix transcription factor
with many alternatively spliced transcripts resulting in mul-
tiple isoforms (14). The gene is expressed in the embryonic
central nervous system (CNS) and many adult tissues (15),
including the mammalian brain (16).
Multiple lines of evidence support a role for TCF4 in the
CNS, especially in its development. TCF4 deletions and
some coding mutations in the gene cause Pitt–Hopkins syn-
drome, an encephalopathy characterized by severe intellectual
disability, a distinctive facial appearance and additional fea-
tures including breathing problems, epilepsy and postnatal
microcephaly (15,17,18). TCF4 interacts with transcription
factors playing key roles in neurodevelopment including
mouse atonal (ato) homolog 1 (Math1) (19), human
achaete–scute homologue 1 (HASH1) (20) and neurogenic
differentiation factor 2 (neuroD2) (16,21). In Tcf4– /– mice,
pontine nuclei development is disrupted (19), whereas mice
overexpressing Tcf4 postnatally in the forebrain display cogni-
tive impairments and deficits in pre-pulse inhibition (16).
Differential expression of TCF4 related to psychosis has
been reported. Decreased expression in blood has been associ-
ated with the psychotic state (22), whereas up-regulation has
been found in both the cerebellar cortex of schizophrenia
Table 2. Previously identified variants showing genome-wide significant association with schizophrenia
SNP Mb Al Freq SGENE-plus + ISC + MGS
(7 946 cases; 19 036 controls)
Primary follow-up
(9 246 cases; 22 356 controls)
Secondary follow-up
(1 014 cases; 1 144
controls)
SGENE-plus + ISC + MGS
and all follow-up
(18 206 cases; 42 536 controls)
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
6p21.3–6p22.1, MHC
rs6913660 27.2 C 0.85 1.19 (1.12, 1.27) 4.6 × 1028 1.09 (1.04, 1.15) 0.00067 1.34 (1.13, 1.57) 0.00050 1.14 (1.10, 1.19) 1.7 × 10211
rs6932590 27.4 T 0.78 1.15 (1.09, 1.21) 5.6 × 1027 1.10 (1.05, 1.15) 6.9 × 1025 1.11 (0.96, 1.28) 0.15 1.12 (1.08, 1.16) 1.6 × 10210
rs13211507 28.4 T 0.92 1.22 (1.12, 1.33) 5.2 × 1026 1.21 (1.13, 1.30) 1.1 × 1027 1.34 (1.08, 1.67) 0.0089 1.22 (1.16, 1.29) 1.4 × 10213
rs3131296 32.3 G 0.87 1.18 (1.10, 1.27) 9.8 × 1026 1.14 (1.07, 1.21) 1.4 × 1025 1.28 (1.07, 1.54) 0.0080 1.16 (1.11, 1.21) 5.1 × 10211
11q24.2, NRGN
rs12807809 124.1 T 0.83 1.16 (1.09, 1.24) 2.3 × 1026 1.09 (1.04, 1.15) 0.00057 1.16 (0.99, 1.37) 0.063 1.12 (1.08, 1.17) 2.8 × 1029
18q21.2, TCF4
rs9960767 51.3 C 0.056 1.27 (1.15, 1.40) 1.8 × 1026 1.16 (1.07, 1.25) 0.00025 1.09 (0.85, 1.41) 0.50 1.20 (1.13, 1.27) 4.2 × 1029
Mb, megabase based on NCBI Build 36; al, allele; freq, average frequency in SGENE-plus controls.
Table 1. Novel variants showing genome-wide significant association with schizophrenia
SNP Mb Al Freq SGENE-plus + ISC + MGS
(7 946 cases; 19 036 controls)
Primary follow-up
(9 246 cases; 22 356 controls)
Secondary follow-up
(1 014 cases; 1 144
controls)
SGENE-plus + ISC + MGS
and all follow-up
(18 206 cases; 42 536 controls)
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
2p15.1, VRK2
rs2312147 58.1 C 0.61 1.11 (1.06, 1.17) 3.7 × 1026 1.08 (1.03, 1.12) 0.00024 1.10 (0.97, 1.24) 0.13 1.09 (1.06, 1.12) 1.9 × 1029
18q21.2, TCF4
rs4309482 50.9 A 0.58 1.10 (1.05, 1.15) 7.1 × 1025 1.08 (1.04, 1.13) 3.6 × 1025 1.06 (0.94, 1.20) 0.34 1.09 (1.06, 1.12) 7.8 × 1029
Mb, megabase based on NCBI Build 36; al, allele; freq, average frequency in SGENE-plus controls.
Human Molecular Genetics, 2011, Vol. 20, No. 20 4079
patients (23) and the brains of mice given phencyclidine
(PCP)—a treatment that mimics the behavioural syndrome
of schizophrenia (22).
A common SNP in intron 3 of TCF4 is strongly associated
with Fuchs’s corneal dystrophy (FCD) (24). This SNP,
rs613872, is weakly correlated with rs4309482 and
rs9960767 (HapMap CEU r2 , 0.1). We find no reports exam-
ining co-occurrence of schizophrenia and FCD.
Two findings of this study, the novel genome-wide signifi-
cant associations and the excess of ORs in the follow-up set
in the same direction as in the discovery data set, support a
role for common sequence variants in schizophrenia heritabil-
ity. The latter finding, like the previous score allele analysis
(2), buttresses the notion that larger sample sizes will allow
the identification of additional common risk alleles. Previous
studies have demonstrated that rare structural variants contrib-
ute to schizophrenia susceptibility (25). Next-generation
sequencing technology should facilitate the discovery of rare
sequence variants conferring risk of schizophrenia. Even-
tually, a collection of variants—rare and common, structural
and single-nucleotide—may account for a substantial pro-
portion of schizophrenia heritability, as has been shown for
other common diseases such as type 2 diabetes (26).
The primary goal of uncovering schizophrenia risk alleles is
to find novel genes and, through them, pathways involved in
the disease. The results revealed here implicate genes involved
in signal transduction (VRK2) and gene expression (TCF4). A
great deal of additional work is required to understand how the
SNPs affect these genes (or possibly other, neighbouring
genes) and how these changes, in turn, lead to schizophrenia.
Nevertheless, the results described here provide a valuable
starting point for investigation of the biological mechanisms
leading to schizophrenia.
MATERIALS AND METHODS
Samples
The genome-wide typed (‘SGENE-plus’; 2 663 cases and
13 498 controls) and meta-analysis samples (5 283 cases and
5 538 controls) used here were identical to those of our orig-
inal GWA paper. Those samples are described in that work
(4) and in the companion papers (2,3). The primary follow-up
samples employed here consist of the follow-up material
from our original GWA study (excluding 460 cases and 677
controls for which DNA was no longer available) and an
additional 4 707 cases and 7 478 controls from Belgium,
Denmark (Aarhus), Denmark (Copenhagen), Ireland (the
Wellcome Trust Case Control Consortium 2), Italy, the Neth-
erlands, Norway, Russia, the UK (Cardiff University) and the
USA [the European-American portion of the Clinical Antipsy-
chotic Trials of Intervention Effectiveness (CATIE) study]
(Supplementary Material, Table S1). The secondary follow-up
samples consisted of 1 014 cases and 1 144 controls from the
Go¨ttingen Research Association for Schizophrenia (GRAS)
(27) study. All cases were diagnosed with schizophrenia, schi-
zoaffective disorder (7%) or persistent delusional disorder
(, 1%) (see the Supplementary Material for further infor-
mation on the various study groups).
Genotyping and association analysis
Genotyping was carried out using Illumina and Affymetrix
genome-wide arrays, Centaurus assays (Nanogen), the Seque-
nom MassArray iPLEX genotyping system and the Roche
LightCycler480 system (Supplementary Material, Table S1).
The Supplementary Material further describes genotyping as
well as sample and marker quality control in each group.
Association analysis was carried out using a likelihood
model as previously described (28). Imputation was performed
for the Ireland (WTCCC2) and UK groups (both typed on
Affymetrix chips) as described in the Supplementary Material.
For the Finnish and CATIE samples, association results were
adjusted for the first 10 or 20, respectively, principal
components using logistic regression. The remaining
genome-wide-typed groups—all of which had genomic
control inflation factions ,1.1—were corrected for potential
population stratification using genomic control (29).
Summary statistics were used to combine association results
from the various study groups as described earlier (4).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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